Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleNeuropharmacology

Celecoxib treatment improves neurological deficit and reduces selective neuronal loss and glial response in rats following transient middle cerebral artery occlusion

Maria Santos-Galdiano, Diego Perez-Rodriguez, Berta Anuncibay-Soto, Enrique Font-Belmonte, Irene F Ugidos, Carlos Cesar Perez-Garcia and Arsenio Fernandez-Lopez
Journal of Pharmacology and Experimental Therapeutics October 5, 2018, jpet.118.251264; DOI: https://doi.org/10.1124/jpet.118.251264
Maria Santos-Galdiano
Universidad de Leon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Diego Perez-Rodriguez
Universidad de Leon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Berta Anuncibay-Soto
Universidad de Leon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Enrique Font-Belmonte
Universidad de Leon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Irene F Ugidos
Universidad de Leon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlos Cesar Perez-Garcia
Universidad de Leon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arsenio Fernandez-Lopez
Universidad de Leon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Background: Areas of selective neuronal loss (SNL) represent the first morphological signs of damage in the penumbra region and are considered putative targets for ischemic stroke therapy. Here we performed a novel assessment of measuring the effects of the anti-inflammatory agent, celecoxib, analyzing simultaneously the different neural populations (neurons, astrocytes and microglia cells) in SNL and non-SNL areas. Methods: Rats were subjected to 1 hour of middle cerebral artery occlusion (MCAO) and treated with celecoxib 1 h and 24 h after ischemia. Infarct volume measurements and triple immunostaining of neurons (NeuN), microglia (IBA I) and astroglia (GFAP) were performed after 12 h and 48 h of reperfusion. Motor response was tested by standard behavioural assays at 3 h, 12 h, 24 h and 48 h. Results: Confocal analysis revealed that the percentage of SNL areas, microglia densities and glial activation increased at 48 h of reperfusion. Celecoxib treatment improved the neurological deficit, reduced the infarct volume by 50% after 48 h of reperfusion, and resulted in a reduced percentage of SNL areas and microglia and astroglia reactivity after 48 h of reperfusion. Conclusions: This study proves for the first time that celecoxib presents post-ischemic neuroprotective effects in a transient MCAO model, prevents, or delays, the presence of SNL areas and reduces glial activation.

  • astrocytes
  • cerebral ischemia
  • COX-2
  • ischemia / reperfusion injury
  • microglia
  • neuroprotection
  • The American Society for Pharmacology and Experimental Therapeutics
Next
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 381 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 381, Issue 2
1 May 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Celecoxib treatment improves neurological deficit and reduces selective neuronal loss and glial response in rats following transient middle cerebral artery occlusion
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleNeuropharmacology

Celecoxib treatment improves neurological deficit and reduces selective neuronal loss and glial response in rats following transient middle cerebral artery occlusion

Maria Santos-Galdiano, Diego Perez-Rodriguez, Berta Anuncibay-Soto, Enrique Font-Belmonte, Irene F Ugidos, Carlos Cesar Perez-Garcia and Arsenio Fernandez-Lopez
Journal of Pharmacology and Experimental Therapeutics October 5, 2018, jpet.118.251264; DOI: https://doi.org/10.1124/jpet.118.251264

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleNeuropharmacology

Celecoxib treatment improves neurological deficit and reduces selective neuronal loss and glial response in rats following transient middle cerebral artery occlusion

Maria Santos-Galdiano, Diego Perez-Rodriguez, Berta Anuncibay-Soto, Enrique Font-Belmonte, Irene F Ugidos, Carlos Cesar Perez-Garcia and Arsenio Fernandez-Lopez
Journal of Pharmacology and Experimental Therapeutics October 5, 2018, jpet.118.251264; DOI: https://doi.org/10.1124/jpet.118.251264
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Antipsychotic-VMAT2 Inhibitor Synergy: Schizophrenia Models
  • Rescue Pharmacology on Disease-Related GRIN Variants
  • Obesity thwarts preconditioning in TBI
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics